Compare · BOLD vs NVO
BOLD vs NVO
Side-by-side comparison of Boundless Bio Inc. (BOLD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BOLD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 3999.5x BOLD ($55.7M).
- Over the past year, BOLD is up 106.7% and NVO is down 21.8% - BOLD leads by 128.4 points.
- BOLD has been more active in the news (14 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for BOLD).
- Company
- Boundless Bio Inc.
- Novo Nordisk A/S
- Price
- $2.48-0.40%
- $50.31-2.25%
- Market cap
- $55.7M
- $222.81B
- 1M return
- +76.51%
- +15.47%
- 1Y return
- +106.67%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 14
- 5
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BOLD
- Large owner Tang Kevin bought $155,646 worth of shares (63,969 units at $2.43) (SEC Form 4)
- Large owner Tang Kevin bought $222,070 worth of shares (91,585 units at $2.42) (SEC Form 4)
- Large owner Tang Kevin bought $141,865 worth of shares (57,210 units at $2.48) (SEC Form 4)
- Large owner Crandell Keith exercised 16,000 shares at a strike of $1.03 and sold $39,840 worth of shares (16,000 units at $2.49) (SEC Form 4)
- Large owner Arch Venture Fund Ix, L.P. exercised 16,000 shares at a strike of $1.03 and sold $39,840 worth of shares (16,000 units at $2.49) (SEC Form 4)
- Large owner Tang Kevin bought $268,880 worth of shares (107,463 units at $2.50) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Boundless Bio Inc.
- Large owner Tang Kevin bought $714,768 worth of shares (286,333 units at $2.50) (SEC Form 4)
- New insider Tang Kevin claimed ownership of 2,247,512 shares (SEC Form 3)
- These Emerging Companies Are Racing Toward Major Catalysts
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S